FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martin Gramatzki

Research Profile

Chemicals & Drugs

Anatomy

Physiology

Antibody-Dependent Cell Cytotoxicity

Living Beings

Mouse

Disorders

Procedures

Concepts & Ideas

Treatment Outcome

Co-author Network

Publications

TOP 3
P Glorius; Martin Gramatzki; Andreas Humpe; C Kellner; F Nimmerjahn; Paul W H I Parren; Roland Repp; M Staudinger; M Stauch; Thomas Valerius; J G J van de Winkel; A Baerenwaldt; F J Beurskens; Michael Dechant; Matthias Peipp
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.
Christian Kellner; Tina Maurer; Paul W H I Parren; Martin Gramatzki; Daniela Hallack; Andreas Humpe; Roland Repp; Thomas Valerius; Jan G J van de Winkel; Matthias Peipp
Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
Sahar Mohseni Nodehi; Matthias Peipp; Roland Repp; Natalie Schub; Matthias Staudinger; Joachim Bräutigam; Martin Gramatzki; Christian Kellner; Andreas Humpe
Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martin Gramatzki (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: P Glorius; Martin Gramatzki; Andreas Humpe; C Kellner; F Nimmerjahn; Paul W H I Parren; Roland Repp; M Staudinger; M Stauch; Thomas Valerius; J G J van de Winkel; A Baerenwaldt; F J Beurskens; Michael Dechant; Matthias Peipp
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.
Leukemia 2013;27(1):190-201.
2012: Christian Kellner; Tina Maurer; Paul W H I Parren; Martin Gramatzki; Daniela Hallack; Andreas Humpe; Roland Repp; Thomas Valerius; Jan G J van de Winkel; Matthias Peipp
Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
Journal of immunology (Baltimore, Md. : 1950) 2012;189(10):5037-46.
2012: Sahar Mohseni Nodehi; Matthias Peipp; Roland Repp; Natalie Schub; Matthias Staudinger; Joachim Bräutigam; Martin Gramatzki; Christian Kellner; Andreas Humpe
Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.
PloS one 2012;7(8):e42426.
2011: Roland Repp; Matthias Staudinger; Thomas Valerius; Patrick H C Van Berkel; Jan G J van de Winkel; Sahar Mohseni Nodehi; Dalia Akramiene; Michael Dechant; Georg H Fey; Pia Glorius; Martin Gramatzki; Christian Kellner; Anja Muskulus; Paul W H I Parren; Matthias Peipp
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Journal of immunological methods 2011;373(1-2):67-78.
2011: Antonio Palumbo; Laura Rosiñol; Jesus F San Miguel; Orhan Sezer; Andrew Spencer; Evangelos Terpos; Sonja Zweegman; Meral Beksac; Joan Bladé; Mario Boccadoro; Sara Bringhen; Michele Cavo; Faith Davies; Meletios A Dimopoulos; Christoph Driessen; Hermann Einsele; Peter Gimsing; Martin Gramatzki; Roman Hàjek; Hans E Johnsen; Fernando Leal Da Costa; Henk Lokhorst; Heinz Ludwig; Maria V Mateos; Gareth Morgan; Pieter Sonneveld
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).
Blood 2011;118(17):4519-29.
2011: Tapani Ruutu; Marc Schnitzler; Matthias Stelljes; Gernot Stuhler; Rudolf Trenschel; Lutz Uharek; Liisa Volin; Axel R Zander; Hermann Einsele; Juergen Finke; Mathias Freund; Sebastian Giebel; Martin Gramatzki; Jerzy Holowiecki; Joachim Kienast; Kajsa Larsson; Miroslaw Markiewicz; Heidrun A Mylius; Uwe Pichlmeier; Roland Repp; Joachim Baumgart; Dietrich W Beelen; Igor Wolfgang Blau; Jochen Casper
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Haematologica 2011;96(9):1344-50.
2011: Daniel Wolff; Michael Schleuning; Stephanie von Harsdorf; Ulrike Bacher; Armin Gerbitz; Michael Stadler; Francis Ayuk; Alexander Kiani; Rainer Schwerdtfeger; Georgia B Vogelsang; Guido Kobbe; Martin Gramatzki; Anita Lawitschka; Mohamad Mohty; Steven Z Pavletic; Hildegard Greinix; Ernst Holler
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2011;17(1):1-17.
2010: Matthias Lüftl; Birthe Sauter-Jenne; Martin Gramatzki; Fritjof Eckert; Lars Jenne
Cutaneous macroglobulinosis deposits in a patient with IgM paraproteinemia/incipient Waldenström macroglobulinemia.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2010;8(12):1000-3.
2010: Monika Engelhardt; Josefina Udi; Martina Kleber; Andrew Spencer; Alberto Rocci; Stefan Knop; Benedetto Bruno; Sara Bringhen; José A Pérez-Simón; Sonja Zweegman; Christoph Driessen; Francesca Patriarca; Martin Gramatzki; Evangelos Terpos; Orhan Sezer; Martin Kropff; Christian Straka; Hans E Johnsen; Anders Waage; Martin Boegsted; Henk Lokhorst; Roman Hájek; Gareth Morgan; Mario Boccadoro; Heinz Ludwig; Michele Cavo; Aaron Polliack; Pieter Sonneveld; Hermann Einsele; Antonio Palumbo
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
Leukemia & lymphoma 2010;51(11):2006-11.
2010: Francesco d'Amore; John Radford; Thomas Relander; Mats Jerkeman; Hervé Tilly; Anders Osterborg; Franck Morschhauser; Martin Gramatzki; Martin Dreyling; Bo Bang; Hans Hagberg
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
British journal of haematology 2010;150(5):565-73.
2010: Christoph Röllig; Christian Thiede; Martin Gramatzki; Walter Aulitzky; Heinrich Bodenstein; Martin Bornhäuser; Uwe Platzbecker; Reingard Stuhlmann; Ulrich Schuler; Silke Soucek; Michael Kramer; Brigitte Mohr; Uta Oelschlaegel; Friedrich Stölzel; M von Bonin; Martin Wermke; Hannes Wandt; Gerhard Ehninger; Markus Schaich
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial.
Blood 2010;116(6):971-8.
2010: Monika Engelhardt; Martina Kleber; Josefina Udi; Ralph Wäsch; Andrew Spencer; Francesca Patriarca; Stefan Knop; Benedetto Bruno; Martin Gramatzki; Fortunato Morabito; Martin Kropff; Antonino Neri; Orhan Sezer; Rom Hajek; Donald Bunjes; Mario Boccadoro; Christian Straka; Michele Cavo; Aaron Polliack; Hermann Einsele; Antonio Palumbo
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.
Leukemia & lymphoma 2010;51(8):1424-43.
2010: Andreas Guenther; Sharon Gordon; Markus Tiemann; Renate Burger; Frank Bakker; Jonathan R Green; Wolfgang Baum; Anke J Roelofs; Michael J Rogers; Martin Gramatzki
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
International journal of cancer. Journal international du cancer 2010;126(1):239-46.
2009: Dorothee Meyer; Sebastian Seth; Jana Albrecht; Michael K Maier; Louis du Pasquier; Inga Ravens; Lutz Dreyer; Renate Burger; Martin Gramatzki; Reinhard Schwinzer; Elisabeth Kremmer; Reinhold Foerster; Günter Bernhardt
CD96 interaction with CD155 via its first Ig-like domain is modulated by alternative splicing or mutations in distal Ig-like domains.
The Journal of biological chemistry 2009;284(4):2235-44.
2009: Renate Burger; Steven Le Gouill; Yu-Tzu Tai; Reshma Shringarpure; Pierfrancesco Tassone; Paola Neri; klaus podar; Laurence Catley; Teru Hideshima; Dharminder Chauhan; Eian Caulder; Claire L Neilan; Kris Vaddi; Jun Li; Martin Gramatzki; Jordan S Fridman; Kenneth C Anderson
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
Molecular cancer therapeutics 2009;8(1):26-35.
2008: Anna Sureda; Stephen Robinson; Carme Canals; Angelo M Carella; Marc A Boogaerts; Dolores Caballero; Ann E Hunter; Lothar Kanz; Shimon Slavin; Jan J Cornelissen; Martin Gramatzki; Dietger Niederwieser; Nigel H Russell; Norbert Schmitz
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(3):455-62.
2007: Benedikt Gahn; N Schub; R Repp; Martin Gramatzki
Triple antifungal therapy for severe systemic candidiasis allowed performance of allogeneic stem cell transplantation.
European journal of medical research 2007;12(8):337-40.
2007: Dennis Löffler; Katja Brocke-Heidrich; Gabriele Pfeifer; Claudia Stocsits; Jorg Hackermuller; Antje K Kretzschmar; Renate Burger; Martin Gramatzki; Conny Blumert; Kay Bauer; Helena Cvijic; A Kerstin Ullmann; Peter F Stadler; Friedemann Horn
Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer.
Blood 2007;110(4):1330-3.
2007: Naoki Hosen; Christopher Park; Naoya Tatsumi; Yusuke Oji; Haruo Sugiyama; Martin Gramatzki; Alan Krensky; Irving L Weissman
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(26):11008-13.
2007: Andreas Humpe; Pal Jansen; Bernd Karsten Tischer; Sabine Schubert; Christian Beck; Ilse-Dorothea Adamzik; Jens-Holger Maas; Alexander Strate; Martin Gramatzki; Joachim Riggert
Cryopreservation of cellular products in a closed-bag system with an incorporated dimethyl sulfoxide-resistant sterile filter outside of cleanroom facilities.
Transfusion 2007;47(6):1033-41.
2007: Silke Meister; Ulrich Schubert; Kirsten Neubert; Kai Herrmann; Renate Burger; Martin Gramatzki; Sabine Hahn; Sandra Schreiber; Sabine Wilhelm; Martin Herrmann; Hans-Martin Jäck; Reinhard E Voll
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Cancer research 2007;67(4):1783-92.
2006: Juergen Rech; Roland Repp; Dorit Rech; Bernhard Stockmeyer; Michael Dechant; Gerald Niedobitek; Martin Gramatzki; Thomas Valerius
A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study.
Leukemia & lymphoma 2006;47(10):2147-54.
2006: A Pachnio; Sebastian Dietrich; Wolfram Klapper; Andreas Humpe; Michael Schwake; Radislav Sedlacek; Martin Gramatzki; Christian Beck
Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
Bone marrow transplantation 2006;38(2):157-67.
2006: Christian Hoffmann; R Repp; Robert Schoch; Benedikt Gahn; N Schub; C Beck; Andreas Humpe; M Kneba; Heinz-August Horst; Norbert Schmitz; Martin Gramatzki
Successful autologous stem cell transplantation in a severely immunocompromised patient with relapsed AIDS-related B-cell lymphoma.
European journal of medical research 2006;11(2):73-6.
2005: Thomas Elter; Peter Borchmann; Holger Schulz; Marcel Reiser; Sven Trelle; Roland Schnell; Markus Jensen; Peter Staib; Timo Schinköthe; Hartmut Stützer; Juergen Rech; Martin Gramatzki; Walter Aulitzky; Ibrahim Hasan; Andreas Josting; Michael Hallek; Andreas Engert
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7024-31.
2005: Edwin Bremer; Douwe F Samplonius; Matthias Peipp; Linda van Genne; Bart-Jan Kroesen; Georg H Fey; Martin Gramatzki; Lou F M H De Leij; Wijnand Helfrich
Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Cancer research 2005;65(8):3380-8.
2004: Wolfram Brugger; J Hirsch; Frank Grünebach; R Repp; Peter Brossart; Wichard Vogel; H-G Kopp; M G Manz; M Bitzer; G Schlimok; M Kaufmann; Arnold Ganser; K Fehnle; Martin Gramatzki; Lothar Kanz
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(11):1691-8.
2004: Katja Brocke-Heidrich; Antje K Kretzschmar; Gabriele Pfeifer; Christian Henze; Dennis Löffler; Dirk Koczan; Hans-Jürgen Thiesen; Renate Burger; Martin Gramatzki; Friedemann Horn
Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation.
Blood 2004;103(1):242-51.
2003: Roland Repp; Heidi H van Ojik; Thomas Valerius; Gerard Groenewegen; G Wieland; C Oetzel; Bernhard Stockmeyer; W Becker; M Eisenhut; H Steininger; YM Deo; Geert H Blijham; Joachim R Kalden; Jan G J van de Winkel; Martin Gramatzki
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.
British journal of cancer 2003;89(12):2234-43.
2003: Renate Burger; Frank Bakker; Andreas Guenther; Wolfgang Baum; Dirk Schmidt-Arras; Teru Hideshima; Yu-Tzu Tai; Reshma Shringarpure; Laurence Catley; Giorgio Senaldi; Martin Gramatzki; Kenneth C Anderson
Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival.
British journal of haematology 2003;123(5):869-78.
2003: Oliver J Ott; Claus Rödel; Martin Gramatzki; Gerald Niedobitek; Rolf Sauer; Gerhard G Grabenbauer
Radiotherapy for stage I-III nodal low-grade non-Hodgkin's lymphoma.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 2003;179(10):694-701.
2003: Roland Repp; U Schaekel; G Helm; Christian Thiede; Silke Soucek; Ulrich Pascheberg; Hannes Wandt; Walter Aulitzky; Heinrich Bodenstein; R Sonnen; H Link; Gerhard Ehninger; Martin Gramatzki
Immunophenotyping is an independent factor for risk stratification in AML.
Cytometry. Part B, Clinical cytometry 2003;53(1):11-9.
2003: Süleyman Yedibela; Thomas Reck; Gerald Niedobitek; Martin Gramatzki; Roland Repp; Werner Hohenberger; Rudolf Ott
Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
Transplant international : official journal of the European Society for Organ Transplantation 2003;16(3):197-201.
2002: Michael Dechant; Gestur Vidarsson; Bernhard Stockmeyer; Roland Repp; Martin J Glennie; Martin Gramatzki; Jan G J van de Winkel; Thomas Valerius
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.
Blood 2002;100(13):4574-80.
2002: Bernhard Stockmeyer; Martin Schiller; Roland Repp; Hanns-Martin Lorenz; Joachim R Kalden; Martin Gramatzki; Thomas Valerius
Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody.
British journal of haematology 2002;118(4):959-67.
2002: Matthias Peipp; Heide Küpers; Domenica Saul; Beate Schlierf; Johann Greil; Susan J Zunino; Martin Gramatzki; Georg H Fey
A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells.
Cancer research 2002;62(10):2848-55.
2002: H Stadick; Bernhard Stockmeyer; Reinhard Kühn; Karl M Schrott; Joachim R Kalden; Martin J Glennie; Jan G J van de Winkel; Martin Gramatzki; Thomas Valerius; D Elsässer
Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?
The Journal of urology 2002;167(2 Pt 1):707-12.
2001: Jens Atzpodien; Holger Kirchner; Hans-Jochen Illiger; Bernd Metzner; D Ukena; H Schott; P J Funke; Martin Gramatzki; S Jürgenson; Thomas Wandert; T Patzelt; Martina Reitz
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.
British journal of cancer 2001;85(8):1130-6.
2001: Erich Gebhart; Wolf Rösler; Martin Gramatzki; Udo Trautmann
FISH monitoring of 100 courses of human leukemias: the cytogenetic viewpoint.
International journal of oncology 2001;19(3):617-23.
2001: Richard Strauss; A Mueller; Markus Wehler; Daniel Neureiter; E Fischer; Martin Gramatzki; Eckhart Hahn
Pseudomembranous tracheobronchitis due to Bacillus cereus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(5):E39-41.
2001: Dirk Hönemann; Manik Chatterjee; Rocco Savino; Kurt Bommert; Renate Burger; Martin Gramatzki; Bernd Dörken; Ralf C Bargou
The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells.
International journal of cancer. Journal international du cancer 2001;93(5):674-80.
2001: Bernhard Stockmeyer; D Elsässer; Michael Dechant; Roland Repp; Martin Gramatzki; Martin J Glennie; Jan G J van de Winkel; Thomas Valerius
Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies.
Journal of immunological methods 2001;248(1-2):103-11.
2001: Renate Burger; A Guenther; Frank Bakker; M Schmalzing; S Bernand; Wolfgang Baum; B Duerr; GM Hocke; H Steininger; Erich Gebhart; Martin Gramatzki
Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma.
The hematology journal : the official journal of the European Haematology Association / EHA 2001;2(1):42-53.
2001: Irmgard Verdorfer; Lukrecija Brecevic; W Saul; B Schenker; M Kirsch; Udo Trautmann; G Helm; Martin Gramatzki; Erich Gebhart
Comparative genomic hybridization-aided unraveling of complex karyotypes in human hematopoietic neoplasias.
Cancer genetics and cytogenetics 2001;124(1):1-6.
2000: Bernhard Stockmeyer; Michael Dechant; Marjolein van Egmond; Alison L Tutt; K Sundarapandiyan; Robert F Graziano; Roland Repp; Joachim R Kalden; Martin Gramatzki; Martin J Glennie; Jan G J van de Winkel; Thomas Valerius
Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(10):5954-61.
2000: Michaela Feuring-Buske; Michael Kneba; Michael Unterhalt; A Engert; Martin Gramatzki; Erhard Hiller; Lorenz Trümper; Wolfram Brugger; Helmut Ostermann; J Atzpodien; Michael Hallek; E Aulitzky; Wolfgang Hiddemann
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
Annals of hematology 2000;79(9):493-500.
1999: Thomas M Behr; Bernhard Wörmann; Martin Gramatzki; Joachim Riggert; Stefan Gratz; Martin Béhé; Frank Griesinger; Robert M Sharkey; H J Kolb; Wolfgang Hiddemann; David M Goldenberg; Wolfgang Becker
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3304s-3314s.
1999: D Elsässer; H Stadick; S Stark; Jan G J van de Winkel; Martin Gramatzki; Karl M Schrott; Thomas Valerius; W Schafhauser
Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma.
Anticancer research 1999;19(2C):1525-8.
1999: R Burger; T E Hansen-Hagge; H G Drexler; Martin Gramatzki
Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines: suggestion for classification by immunophenotype and T-cell receptor studies.
Leukemia research 1999;23(1):19-27.
1998: Martin Gramatzki; W D Ludwig; R Burger; P Moos; Peter Rohwer; C Grünert; A Sendler; Joachim R Kalden; R Andreesen; F Henschke; G Moldenhauer
Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia.
Experimental hematology 1998;26(13):1209-14.
1998: Thomas Harrer; J Schwab; Wilhelm G. Struff; M Schmitt; J H Ficker; W Rödl; H Parsch; Joachim R Kalden; Martin Gramatzki
Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS.
Infection 1998;26(6):368-74.
1998: D Würflein; Michael Dechant; Bernhard Stockmeyer; Alison L Tutt; P Hu; Roland Repp; Joachim R Kalden; Jan G J van de Winkel; A L Epstein; Thomas Valerius; Martin J Glennie; Martin Gramatzki
Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
Cancer research 1998;58(14):3051-8.
1998: Wolf Rösler; B Manger; R Repp; Joachim R Kalden; Martin Gramatzki
Autologous PBPCT in a patient with lymphoma and Sjögren's syndrome: complete remission of lymphoma without control of the autoimmune disease.
Bone marrow transplantation 1998;22(2):211-3.
1998: Renate Burger; Frank Neipel; Bernhard Fleckenstein; Rocco Savino; Gennaro Ciliberto; Joachim R Kalden; Martin Gramatzki
Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells.
Blood 1998;91(6):1858-63.
1998: Tanja Fehm; E Beck; Thomas Valerius; Martin Gramatzki; Wolfram Jäger
CA 125 elevations in patients with malignant lymphomas.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1998;19(4):283-9.
1997: Thomas Valerius; Bernhard Stockmeyer; Annemiek van Spriel; Robert F Graziano; IE van den Herik-Oudijk; Roland Repp; YM Deo; J Lund; Joachim R Kalden; Martin Gramatzki; Jan G J van de Winkel
FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
Blood 1997;90(11):4485-92.
1997: Martin Gramatzki; Thomas Valerius
[Antibodies as specific tumor therapy agents. Wishful thinking or reality?].
Der Internist 1997;38(11):1055-62.
1997: Thomas Valerius; D Würflein; Bernhard Stockmeyer; Roland Repp; Joachim R Kalden; Martin Gramatzki
Activated neutrophils as effector cells for bispecific antibodies.
Cancer immunology, immunotherapy : CII 1997;45(3-4):142-5.
1997: Thomas Valerius; D Elsässer; Roland Repp; Jan G J van de Winkel; Martin Gramatzki; Martin J Glennie
HLA class II antibodies recruit G-CSF activated neutrophils for treatment of B cell malignancies.
Leukemia & lymphoma 1997;26(3-4):261-9.
1997: Bernhard Stockmeyer; Thomas Valerius; Roland Repp; IA Heijnen; H J Bühring; YM Deo; Joachim R Kalden; Martin Gramatzki; Jan G J van de Winkel
Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Cancer research 1997;57(4):696-701.
1996: W Baum; H Steininger; HJ Bair; Wolfgang Becker; T E Hansen-Hagge; Michael Kressel; Elisabeth Kremmer; Joachim R Kalden; Martin Gramatzki
Therapy with CD7 monoclonal antibody TH-69 is highly effective for xenografted human T-cell ALL.
British journal of haematology 1996;95(2):327-38.
1996: D Elsässer; Thomas Valerius; Roland Repp; G J Weiner; YM Deo; Joachim R Kalden; Jan G J van de Winkel; George T Stevenson; Martin J Glennie; Martin Gramatzki
HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.
Blood 1996;87(9):3803-12.
1995: W S Becker; T M Behr; F Cumme; W Rössler; Jörg Wendler; P M Kern; Martin Gramatzki; Joachim R Kalden; David M Goldenberg; F G Wolf
67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma.
Cancer research 1995;55(23 Suppl):5771s-5773s.
1995: Roland Repp; Thomas Valerius; G Wieland; W Becker; H Steininger; YM Deo; G Helm; Martin Gramatzki; Jan G J van de Winkel; N Lang
G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
Journal of hematotherapy 1995;4(5):415-21.
1995: Wolfgang Becker; UM Schrell; Michael Buchfelder; Johannes Hensen; Jörg Wendler; Martin Gramatzki; F Wolf
Somatostatin receptor expression in the thyroid demonstrated with 111In-octreotide scintigraphy.
Nuklearmedizin. Nuclear medicine 1995;34(3):100-3.
1995: Erich Gebhart; Thomas Liehr; P Harrer; S Reichardt; G Schmitt; K Thoma; Martin Gramatzki; Udo Trautmann
Determination by interphase-FISH of the clonality of aberrant karyotypes in human hematopoietic neoplasias.
Leukemia & lymphoma 1995;17(3-4):295-302.
1995: Martin Gramatzki; R Burger; G Strobel; Udo Trautmann; C R Bartram; G Helm; Gerd Horneff; Saifeddin Alsalameh; M Jonker; Erich Gebhart
Therapy with OKT3 monoclonal antibody in refractory T cell acute lymphoblastic leukemia induces interleukin-2 responsiveness.
Leukemia 1995;9(3):382-90.
1994: R Burger; Jörg Wendler; K Antoni; G Helm; Joachim R Kalden; Martin Gramatzki
Interleukin-6 production in B-cell neoplasias and Castleman's disease: evidence for an additional paracrine loop.
Annals of hematology 1994;69(1):25-31.
1994: J Greil; Martin Gramatzki; R Burger; Rolf Marschalek; M Peltner; Udo Trautmann; T E Hansen-Hagge; C R Bartram; Georg H Fey; K Stehr
The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7.
British journal of haematology 1994;86(2):275-83.
1994: Udo Trautmann; Martin Gramatzki; M Krauss; A Friz; Thomas Liehr; Erich Gebhart
Tetrasomy 8 as a clonal anomaly in myeloid neoplasias.
Cancer genetics and cytogenetics 1994;72(2):101-4.
1993: Wolfgang Becker; U Dölkemeyer; Martin Gramatzki; M U Schneider; J Scheele; F Wolf
Use of immunoscintigraphy in the diagnosis of fever of unknown origin.
European journal of nuclear medicine 1993;20(11):1078-83.
1993: Thomas Valerius; Roland Repp; T P de Wit; S Berthold; E Platzer; Joachim R Kalden; Martin Gramatzki; Jan G J van de Winkel
Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy.
Blood 1993;82(3):931-9.
1992: Udo Trautmann; A Rubbert; Martin Gramatzki; F Henschke; Erich Gebhart
Multiple chromosomal changes and karyotypic evolution in a patient with myelofibrosis.
Cancer genetics and cytogenetics 1992;61(1):6-10.
1991: Roland Repp; Thomas Valerius; A Sendler; Martin Gramatzki; Heinrich Iro; Joachim R Kalden; E Platzer
Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.
Blood 1991;78(4):885-9.
1991: Martin Gramatzki; R Burger; J Kraus; U Lauer; Peter Rohwer; G Eger; Joachim R Kalden; F Henschke
Monoclonal antibodies EBU-141 (CDw75) and EBU-65 allow reliable distinction between mature and pre-B-cell tumors in suspension and on tissue sections.
Annals of hematology 1991;63(1):20-6.
1988: Martin Gramatzki; Gerd R Burmester; H J König; F Henschke; Joachim R Kalden
Synovial fluid involvement in null cell acute lymphoblastic leukemia diagnosed with monoclonal antibodies.
The Journal of rheumatology 1988;15(3):500-4.